The media and stock market are again atwitter with news of another supposed cancer breakthrough. Avastin (search), a drug developed by biotech giant Genentech (search), reportedly extended the median survival time of terminally ill …
Shares of Genentech, the South San Francisco biotech leader, took a pounding yesterday after the firm's Swiss parent said it would sell as much as 17 percent of its stake to provide investors with a greater supply of the much-in-demand …
While it seems clear $89 a share won’t do it — the market has already pushed Genentech stock to $95 and some analysts are talking well over $100 — the Basel-based drugs giant can afford to bide its time. With 56 percent of the …
While Mylan said it expects to be the first biosimilar in the market, after getting global licenses from Genentech and Roche under a settlement ... even then the US FDA approval may still give its stock a boost due to the certainty of …
A pile of stock options. But as much as these professional entrapments ... and …
And ZymoGenetics and Genentech have more in common than a portfolio management strategy, as both are affiliated with large pharmaceutical companies that hold significant equity stakes, giving them some shelter from the vagaries of stock
More than a quarter of patients given the four-drug combination suffered serious side effects. Sandra Horning, chief medical officer at Roche's Genentech unit, said …
Biotechnology firms MedImmune and Genentech settled a lawsuit over a patented ... Fourth-quarter sales of Synagis were $480 million. Genentech's stock rose 67 cents yesterday, to $68.89, and AstraZeneca's shares rose 1 cent, to …
Shares of NewLink Genetics Corp. plunged 31% in premarket trade Thursday, putting them on track to open at a more …
The decrease in selling, general and administrative expenses was primarily a result of decreases in marketing costs due to a decrease in losses under the collaboration agreement with Genentech and stock-based compensation; those …